Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
40.61 USD | +2.34% | -1.69% | -32.16% |
Financials (USD)
Sales 2024 * | 822M | Sales 2025 * | 1.22B | Capitalization | 4.93B |
---|---|---|---|---|---|
Net income 2024 * | -112M | Net income 2025 * | 150M | EV / Sales 2024 * | 5.61 x |
Net cash position 2024 * | 317M | Net cash position 2025 * | 815M | EV / Sales 2025 * | 3.38 x |
P/E ratio 2024 * |
-44.6
x | P/E ratio 2025 * |
36.4
x | Employees | 704 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.68% |
Latest transcript on Apellis Pharmaceuticals, Inc.
1 day | +2.34% | ||
1 week | -1.69% | ||
Current month | -8.10% | ||
1 month | -15.27% | ||
3 months | -40.69% | ||
6 months | -16.10% | ||
Current year | -32.16% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 54 | 09-09-24 | |
Cedric Francois
FOU | Founder | 51 | 09-09-24 |
Timothy Sullivan
DFI | Director of Finance/CFO | 53 | 17-09-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alec Machiels
FOU | Founder | 51 | 09-09-24 |
Director/Board Member | 65 | 13-06-30 | |
Andrew Dunlop
BRD | Director/Board Member | 52 | 10-02-28 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.61% | 0 M€ | 0.00% | - | |
0.45% | 0 M€ | 0.00% | - | |
0.19% | 4 M€ | +20.15% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-24 | 40.61 | +2.34% | 1,281,356 |
24-05-23 | 39.68 | -8.99% | 1,942,997 |
24-05-22 | 43.6 | +2.44% | 1,259,809 |
24-05-21 | 42.56 | -1.53% | 1,084,601 |
24-05-20 | 43.22 | +4.62% | 884,326 |
Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.16% | 4.93B | |
-2.00% | 90.02B | |
-1.18% | 39.15B | |
-15.83% | 31.71B | |
+62.86% | 26.47B | |
-21.68% | 14.34B | |
-8.73% | 12.89B | |
-15.05% | 11.18B | |
-45.69% | 10.97B | |
+4.94% | 8.94B |
- Stock Market
- Equities
- APLS Stock